Recent advances in genomics are reshaping how researchers and clinicians approach rare cancers—malignancies that affect fewer than 200,000 people in the United States each year. Because these cancers are infrequent, they historically received less research investment, and treatment options often lagged behind those for more common tumors. Genomics, the comprehensive study of an organism’s complete set of DNA, including all of its genes, now offers a powerful pathway to identify the precise genetic drivers of these diseases and to develop therapies that target those drivers directly. This article explores how genomics is accelerating the discovery of targeted treatments for rare cancers, the technologies involved, current challenges, and what the future holds.

The Role of Genomics in Unlocking Rare Cancer Biology

Genomics enables scientists to read the entire genetic code of a tumor—not just a few genes but the full exome or genome. By comparing the DNA of cancer cells with that of healthy cells from the same patient, researchers can pinpoint mutations that are unique to the malignancy. For rare cancers, where conventional pathology classifications may offer little guidance, this molecular profiling can reveal unexpected vulnerabilities. For example, gastrointestinal stromal tumors (GISTs) were once poorly understood, but genomic studies showed that most cases harbor mutations in the KIT or PDGFRA genes, leading directly to the development of the targeted drug imatinib. Similarly, inflammatory myofibroblastic tumors frequently carry ALK gene rearrangements, making them susceptible to ALK inhibitors originally approved for lung cancer.

Advanced Sequencing Technologies

Next-generation sequencing (NGS) platforms have dramatically reduced the cost and increased the speed of genomic analysis. Whole-exome sequencing (WES) reads the protein-coding regions—about 1–2% of the genome—where most disease-causing mutations are found. Whole-genome sequencing (WGS) reads the entire DNA, capturing non-coding regions that can also influence cancer behavior. For rare cancers, WES is often sufficient to identify actionable mutations. RNA sequencing adds another layer by measuring gene expression and detecting fusion genes, which are common in many rare sarcomas and leukemias. Liquid biopsy, which analyzes circulating tumor DNA from a simple blood draw, is an emerging tool that can detect mutations non-invasively, especially useful when tumor tissue is limited.

Identification of Genetic Mutations

The primary goal of genomic analysis in rare cancers is to identify mutations that can be targeted by existing drugs or that point toward new drug development. Beyond the well-known TP53 and KRAS mutations, which are more common in frequent cancers, rare cancers often exhibit unique genomic signatures. For instance, epithelioid hemangioendothelioma, a rare vascular tumor, almost always carries a CAMTA1 rearrangement. Alveolar soft part sarcoma is driven by a ASPSCR1–TFE3 fusion. By cataloging such mutations in publicly available databases like the ClinVar or the AACR Project GENIE, researchers can match rare tumor profiles with known targeted agents. This approach has led to clinical trials where patients with rare cancers are enrolled based on their tumor’s genetic fingerprint rather than its histology—a paradigm known as “basket trials.”

From Mutation to Targeted Therapy: Development Pathways

Once a driver mutation is confirmed in a rare cancer, the path to a targeted therapy involves several steps: preclinical validation, drug design or repurposing, and clinical testing. Because rare cancers have small patient populations, traditional large-scale randomized trials are often infeasible. Instead, regulatory agencies like the FDA may accept data from single-arm trials or from combination analyses across multiple rare tumor types sharing the same mutation.

Direct Targeting of Mutated Proteins

Many targeted therapies are small molecules designed to inhibit the abnormal protein produced by a mutated oncogene. For example, the BRAF V600E mutation—found in several rare cancers including hairy cell leukemia, Erdheim-Chester disease, and some melanomas—can be blocked by drugs like vemurafenib. Similarly, NTRK gene fusions, which occur in rare cancers such as infantile fibrosarcoma and secretory breast carcinoma, are effectively treated by the selective TRK inhibitor larotrectinib. The success of these agents demonstrates that a common genomic target can be exploited across multiple rare cancer types, even when the underlying histologies differ.

Repurposing Existing Drugs

Because drug development for a novel compound is expensive and time-consuming, repurposing drugs already approved for other indications is a practical strategy for rare cancers. If genomic profiling reveals a mutation that is known to respond to a particular drug in a common cancer, the same drug can be tested in the rare cancer. For instance, crizotinib, originally approved for ALK-positive non-small cell lung cancer, is now used to treat ALK-rearranged inflammatory myofibroblastic tumors. The key is having robust genomic data to make the connection. Collaborative initiatives like the NCI Exceptional Responders Initiative study patients who showed dramatic responses to standard therapies, often revealing unexpected genomic vulnerabilities that can be replicated.

Challenges in Genomics-Driven Therapy for Rare Cancers

Despite the promise, applying genomics to treat rare cancers is not without obstacles. Three main challenges dominate: sample and data scarcity, tumor heterogeneity, and high costs.

Limited Sample Sizes

With so few patients, accumulating enough genomic data to identify recurrent mutations is difficult. A mutation that occurs in only 1% of a common cancer may still represent thousands of patients, but in a rare cancer, that same frequency translates to only a handful of individuals. This makes it hard to prove that a particular mutation is truly driver and not a passenger. Collaborative international registries, such as the Rare Cancers Europe registry, are pooling data to overcome this limitation. Artificial intelligence and machine learning are also being used to infer driver status from small datasets by integrating information from protein structure, conservation, and other genomic features.

Tumor Heterogeneity

Even within a single rare cancer type, tumors may be genetically diverse. For example, rhabdomyosarcomas include subtypes with PAX3/7–FOXO1 fusions as well as fusion-negative forms driven by distinct mutations. This heterogeneity means that a targeted therapy effective for one subset may not work for another. Additionally, as tumors evolve under treatment, new resistance mutations can emerge. Genomic monitoring through repeated liquid biopsies is being investigated to detect resistance early and adjust therapy accordingly.

Cost and Access

Sequencing a tumor’s whole exome or genome still costs several thousand dollars, and not all healthcare systems cover it. Furthermore, many rare cancer patients are treated at community hospitals that lack genomic testing infrastructure. Efforts to reduce costs, such as targeted gene panels that cover only the most actionable mutations, are helping, but the ideal is broad access to comprehensive profiling. Pharmaceutical companies and nonprofit organizations have established patient assistance and free testing programs, but coverage remains uneven globally.

Future Directions: Precision Medicine for All Rare Cancers

The next decade promises to accelerate the integration of genomics into routine care for rare cancers. Several trends are converging to make this possible.

Integration with Immunotherapy

Genomics is also informing immunotherapy strategies for rare cancers. Tumors with a high mutational burden often respond better to checkpoint inhibitors, and genomic profiling can identify these cases. For example, some rare cancers caused by mismatch repair deficiency, such as a subset of uterine sarcomas, are highly sensitive to pembrolizumab. Additionally, neoantigens predicted from genomic data can be used to design personalized cancer vaccines, an approach currently being tested in clinical trials for rare tumor types.

Gene Editing and Alternative Modalities

Technologies like CRISPR-Cas9 open the possibility of directly correcting driver mutations, though this remains largely preclinical. For rare cancers with a single, well-defined genetic cause, such as certain germline mutations in BRCA1/2 that predispose to rare ovarian cancers, gene editing could one day offer a cure. More immediately, antisense oligonucleotides and RNA interference are being developed to knock down fusion oncogenes, like EWSR1–FLI1 in Ewing sarcoma, at the mRNA level.

Artificial Intelligence in Rare Cancer Genomics

Machine learning algorithms are becoming indispensable for interpreting the vast amounts of genomic data generated from rare tumors. AI can prioritize mutations for functional testing, predict drug sensitivity based on molecular patterns, and even suggest combination therapies that target both the primary driver and likely resistance pathways. Tools like OncoKB and CIViC are already providing curated knowledge bases that clinicians can use to match mutations to therapies.

Conclusion

Genomics has fundamentally changed the landscape for rare cancer patients. Instead of being resigned to a bleak prognosis with few options, many can now receive therapies designed to attack the specific genetic weaknesses of their tumors. The success stories—imatinib for GIST, larotrectinib for NTRK fusion-positive sarcomas, and many others—demonstrate that despite the challenges of rarity, molecular insights can yield powerful clinical outcomes. Continued investment in collaborative research, cost reduction, and data sharing will be essential to ensure that all rare cancer patients, regardless of where they live, can benefit from the genomic revolution. The future of rare cancer therapy lies not in broad chemotherapy but in precision—guided by the unique DNA of each patient’s disease.